U.S. Food and Drug Administration.pptVIP

* * * * * * U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated. ASCO/FDA Public Workshop onClinical Trials Endpoints inColorectal Cancer Rectal Cancer Endpoints November 12, 2003 Evolution of Adjuvant Treatment Stage II/III Rectal Cancer (T3/T4, N+) Surgical Treatment + Radiation Therapy or Chemotherapy + Post-operative Chemoradiation Therapy + Neoadjuvant Chemoradiation Therapy and Post-operative C